Erythromelalgia is an uncommon condition characterised by episodes of burning pain, increased skin temperature, and redness, most frequently affecting the feet. Although its name is unfamiliar to many people, its effects can be profound: walking, wearing shoes, sleeping, and working may become difficult. Symptoms range from occasional discomfort to persistent, disabling pain. The condition involves abnormal interactions between peripheral nerves and the small blood vessels supplying the skin. Recognising its characteristic presentation, investigating possible underlying disease, and developing an individualised management plan are essential, particularly because some seemingly helpful remedies can damage the feet.
Clinical features and triggers
The typical episode involves hot, painful, red feet, often affecting the toes and soles. Both feet are commonly involved, although symptoms can be asymmetrical or confined to one foot. Redness may be less obvious in darker skin, making warmth, swelling, and the symptom history particularly important. Some people initially experience itching or tingling that progresses to intense burning. Episodes can last minutes, hours, or occasionally days; others experience relatively continuous symptoms.
Heat is the most characteristic trigger. Warm weather, hot baths, exercise, tight footwear, and heavy bedding may provoke attacks. Standing with the feet dependent can also worsen symptoms, while elevation and gentle cooling often provide relief. Alcohol, spicy foods, and emotional stress trigger symptoms in some individuals. Night-time flares are particularly disruptive because warmth beneath bedclothes can prevent sleep. Repeated pain and sleep disturbance can subsequently affect mood, concentration, mobility, and social participation.
Causes and mechanisms
Erythromelalgia is generally classified as primary or secondary. Primary disease may be inherited, occur sporadically, or have no identifiable cause. Some inherited cases involve variants in the SCN9A gene, which encodes the Nav1.7 sodium channel in pain-sensing nerves. These variants can make nerves excessively excitable, allowing normally tolerable warmth to generate severe pain. However, not everyone with primary erythromelalgia has an identifiable SCN9A variant.
Secondary erythromelalgia occurs in association with another disorder or, occasionally, medication exposure. Important associations include essential thrombocythaemia and polycythaemia vera, blood disorders involving excessive production of particular blood cells. Peripheral neuropathies and certain autoimmune conditions are other recognised associations. Mechanisms differ between patients: abnormal nerve signalling, disturbed regulation of skin blood flow, and platelet-mediated microvascular problems may contribute. Consequently, visibly red, warm feet do not necessarily indicate healthy tissue perfusion; increased superficial blood flow may coexist with inefficient oxygen delivery in some proposed disease models.
Diagnosis and differential diagnosis
Diagnosis is primarily clinical because no single test reliably confirms every case. A clinician assesses the relationship between burning pain, warmth, colour changes, triggers, and relief. Photographs taken during spontaneous attacks are useful when the feet appear normal at an appointment. A symptom diary can document timing, footwear, activity, and environmental temperature without deliberately provoking painful episodes.
Assessment should include vascular, neurological, and skin examination. A full blood count is important when investigating associated blood disorders, while further testing depends on the history and examination. Follow-up blood counts may be appropriate because erythromelalgia can precede recognition of a myeloproliferative disorder. Genetic testing is considered selectively, especially with early onset or a strong family history.
Other causes of painful red feet must be considered, including cellulitis, gout, contact dermatitis, peripheral neuropathy, and complex regional pain syndrome. A newly hot, swollen foot in someone with diabetes and neuropathy also requires urgent assessment for Charcot neuroarthropathy. Fever, spreading redness, wounds, or sudden unilateral swelling should not automatically be attributed to erythromelalgia.
Conservative management and foot protection
Management begins with education and practical trigger reduction. Lightweight, breathable footwear with adequate width can minimise heat retention and pressure. Socks should be selected according to comfort and moisture control rather than assumed therapeutic benefit. Pacing activity, taking breaks from prolonged standing, and keeping the sleeping environment comfortably cool may reduce attacks. Complete inactivity should be avoided where possible, because deconditioning can create additional disability.
Cooling requires particular caution. A fan or a briefly applied cool, wrapped gel pack may help, but ice, freezing packs, and cold-water immersion should be avoided. Repeated soaking can cause maceration, ulceration, infection, and cold injury. Relief can encourage increasingly prolonged cooling, creating a damaging cycle. People with reduced sensation or poor circulation are especially vulnerable. Gentle cooling, skin inspection, and elevation are safer principles than attempting to make the feet extremely cold.
Podiatric care can address footwear difficulties, pressure lesions, skin damage, and safe activity. Orthoses do not treat the underlying disorder, although selected modifications may improve comfort when mechanical problems coexist. Any device must avoid excessive bulk, pressure, or heat retention.
Regular review is valuable because tolerance of footwear and activity can change over time. Patients should report new blisters, cracks, or ulcers promptly rather than intensifying cooling. Coordinated care between primary care, dermatology, neurology, haematology, and podiatry may be needed, depending on the suspected cause and complications. Treatment plans should account for work demands, sleep disruption, and access to suitable footwear.
Medical treatment and prognosis
Treating an identifiable underlying disorder is central to secondary erythromelalgia. Aspirin can be particularly effective in platelet-mediated erythromelalgia associated with myeloproliferative disease, but it is not a universal treatment and should not be started without medical assessment. Bleeding risk, interactions, and contraindications must be considered.
Other treatments aim to reduce pain or modify nerve activity. Options include topical lidocaine, compounded preparations, gabapentin or pregabalin, and selected antidepressants used for neuropathic pain. Sodium-channel blockers, such as mexiletine or carbamazepine, may help selected patients, including some with inherited disease. These medicines require appropriate supervision and sometimes specialist monitoring. Responses vary substantially, and evidence for many treatments comes from small studies or case reports rather than large trials. Refractory cases may require specialist pain services; invasive treatments are reserved for carefully selected circumstances.
Prognosis is variable. Some people achieve reasonable control through trigger management and medication, whereas others experience persistent symptoms and considerable functional limitation. Psychological support and pain rehabilitation can improve coping without implying that the symptoms are imaginary. Ultimately, effective care combines accurate diagnosis, investigation of treatable causes, protection of vulnerable skin, and realistic, collaborative treatment goals. For erythromelalgia affecting the feet, preserving comfortable movement and preventing treatment-related injury are as important as reducing the burning pain itself.